Baricitinib for Prurigo nodularis: A pilot study on efficacy and safety
- Conditions
- Prurigo nodularisBaricitinib
- Registration Number
- TCTR20230227002
- Lead Sponsor
- Thammasat university hospital
- Brief Summary
This pilot investigation underscores the potential of baricitinib in Prurigo nodularis treatment, offering rapid clinical responses. However, larger and longer randomized controlled trials are needed to ascertain the efficacy, durability, and safety of baricitinib in Prurigo nodularis treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 12
moderate to severe prurigo nodularis (>= 20 nodules) persist 6 months or more
1.Chronic pruritus not from Prurigo nodularis
2.Have latent or active Tuberculosis, HBV infection, HCV infection, HIV infection
3.Have history of Myocardial infarction, Unstable ischemic heart disease
4.Have history of Heart failure within 12 weeks before enrollment
5.Have history of Stroke
6.Have history of Deep vein thrombosis or pulmonary thromboembolism
7.Have history of uncontrolled disease eg. uncontrolled infection, active cancer
8.Currently on systemic immunosuppressants within 4 weeks before enrollment
9.hemoglobin less than 10.0 g/dL, total white blood cell less than 2500 cells/uL, neutropenia less than 1200 cells/uL, lymphopenia less than 750 cells/uL, thrombocytopenia less than 100000 cells/uL
10.Prenant woman or planned pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method itchy scale, number of lesions 12 weeks picture, Investigator global assessment , Prurigo nodularis severity , pruritus numerical rating scale, Dermatology Life Quality Index
- Secondary Outcome Measures
Name Time Method safety 12 weeks blood test, inquiry